Troubled J&J vaccine manufacturer Emergent promises to fix plant
Companies, agencies, institutions, etc
Johnson & Johnson’s
Emergent
Emergent BioSolutions Inc.
the Food and Drug Administration
FDA
Bloomberg News
Emergent’s
J&J
AstraZeneca Plc
the Centers for Disease Control and Prevention
Bayview
House
Serum Institute of India
People
Bloomberg
Jake Sargent
Robert Kramer
Al Jazeera
Groups
Americans
Democrats
English
Physical locations
No matching tags
Places
Bayview
Locations
United States
U.S.
New York
Baltimore
Gaithersburg
Maryland
California
US
Finland
Poland
Spain
Haiti
Events
No matching tags
Summary
Johnson & Johnson’s single-shot COVID-19 vaccine was expected to be a crucial part of United States immunisation efforts, but Emergent’s manufacturing problems have sharply curtailed the number of doses available.Emergent BioSolutions Inc. is promising the Food and Drug Administration a series of fixes in response to an inspection that led to a halt in production at a company facility that had been making Johnson & Johnson’s Covid-19 vaccine.The contract manufacturer said in a letter to the FDA dated April 30 that it would strengthen its biowaste handling processes, put in place new requirements for wearing protective gowns and deliver training to facility personnel, among other steps to ensure the quality of the vaccine, after agency inspectors cited myriad problems in a report earlier that month.Bloomberg News obtained Emergent’s response to FDA investigators via an information request.
As said here by Al Jazeera